Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Theratechnologies

Theratechnologies to Present Preliminary Safety and Efficacy Data from Phase 1 Trial of Sudocetaxel Zendusortide in Heavily Pretreated Cancer Patients at ASCO 2023
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies Reports on its Annual Meeting of Shareholders
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies’ Trogarzo® (Ibalizumab-uiyk) Shortens Time to HIV Undetectability and Extends Durability of Undetectability and Viral Suppression in a Matched Treatment Comparison
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies Data Presentations at AACR 2023 Showcase Potential of Sudocetaxel Zendusortide as a Single Agent and in Combination with other Anticancer Therapies
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies Reports Financial Results and Business Updates for First Quarter 2023
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies to Announce First Quarter 2023 Financial Results and Provide Business Update
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies to Present Preclinical Data at AACR Demonstrating Synergy Between TH1902 and Anti-PD-L1 Immunotherapy in Cold Tumor Model
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies Receives Nasdaq Notification Letter Regarding Share Price
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies Reports Financial Results and Business Updates for the Fourth Quarter and Full Year Fiscal 2022
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies Announces Amendment to its Term Loan Facility With Affiliates of Marathon Asset Management
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies Presents New Tesamorelin Data Demonstrating Improvement of Metabolic Syndrome in People with HIV
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies Announces Path to Resume TH1902 Clinical Development
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies to Announce Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Open Letter to Shareholders from CEO Paul Levesque
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies Announces Update from Ongoing TH1902 Study
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies Reports Data Showing High Expression of Sortilin (SORT1) in Multiple Solid Tumors from Tissue Microarrays
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies Reports Financial Results for the Third Quarter of Fiscal 2022 and Provides Business Update
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies Presents Data Demonstrating High Expression of Sortilin (SORT1) in Multiple Tumor Types at 34th EORTC-NCI-AACR Symposium
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies’ Trogarzo® Approved by FDA for 30-Second Intravenous (IV) Push, Simplifying HIV Treatment for Heavily Treatment-Experienced Population
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies Announces Closing of Funding of $40 Million Under the Terms of its Credit Agreement
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.